Mimedx (MDXG) FCF Margin (2011 - 2026)

Mimedx (MDXG) posted FCF Margin of 16.49% for Q2 2026, down 843.11% sequentially from 2.22% in Q1 2026, and down 3093.0% YoY from 0.55% in Q2 2025.

Mimedx (MDXG) FCF Margin (2011 - 2026) Analysis & Trends

Mimedx has reported FCF Margin for 16 years, with the latest figure at 16.49% in Q2 2026.

Quarterly FCF Margin fell 3093.0% year-over-year to 16.49% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 12.53% (down 318.0% YoY) and the FY2025 annual result came in at 17.43%, down 133.0% from the prior year.
FCF Margin eased to 16.49% in Q2 2026 per MDXG's latest filing, from 2.22% in the prior quarter.
Over five years, FCF Margin peaked at 25.62% in Q3 2025 and troughed at 17.56% in Q1 2022.
A 5-year average of 7.55% and a median of 8.42% in 2023 frame the typical range for FCF Margin.
The sharpest annual moves came in 2023 and 2026: FCF Margin jumped 2514 bps in 2023, then sank 3093 bps in 2026.
Over 5 years, FCF Margin stood at 8.46% in 2022, then soared by 220 bps to 10.18% in 2023, then jumped by 96 bps to 19.93% in 2024, then increased by 5 bps to 20.89% in 2025, then tumbled by 179 bps to 16.49% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 16.49%, 2.22%, and 20.89% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	13.35%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,594.17%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	70.82%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.62%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-22.35%
10	Mimedx	622.24 Mn	486.40 Mn	44.38 Mn	-16.49%

Download Data